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Current influenza virus vaccines are prepared using high-yield reassortant virus strains obtained from a mixed infection
of the new virus strain and a prototype high-yielding virus strain. The high-titered reassortant virus strain used as vaccine
seed virus possesses the recent virus HA and NA and contains the internal genes from the high-growing prototype parent.
We established a human CD81 cytotoxic T cell (CTL) line, 10-2C2, which recognizes an HLA-A2.1-restricted influenza A virus
H1, H2, H3 cross-reactive T cell epitope on amino acids 122–130 of the NS1 protein, and unexpectedly we observed that there
was decreased lysis of target cells infected with the A/Texas/36/91 (H1N1) vaccine virus strain compared to the lysis of
target cells infected with the prototype A/PR/8/34 (H1N1) virus. RT-PCR results showed that the A/Texas vaccine virus strain
contained a quasispecies. Approximately 50% of viral RNA of the NS1 gene had a nucleotide substitution that resulted in the
N3 K amino acid change at the sixth position of the nonamer peptide. Current influenza vaccines are inactivated and do not
contain the NS1 protein; however, future influenza vaccines may include live attenuated vaccines and with this mutation a
live virus would fail to induce a CD81 CTL response to this epitope in individuals with HLA-A2.1, a very common allele, and
potentially have reduced efficacy. © 1999 Academic Press
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Current influenza vaccines are prepared by inocula-
ion of virus into embryonated hens’ eggs, harvesting of
luids, and purification of concentrated virus suspen-
ions, which are then formalin-inactivated and detergent-
isrupted. To obtain a seed virus to produce higher virus
ields in vaccine production, a reassortant virus that is
repared from a mixed infection of the new virus strain
nd a prototype high-yielding virus strain may be used.
rowth in eggs at high dilution is sought and the selec-
ion for progeny virus with the external glycoproteins, HA
nd NA, of the recent virus strain is performed with
ntibodies to neutralize progeny virus with prototype HA
nd NA. The high-yielding reassortant virus strain pos-
esses the recent virus HA and NA and contains the
nternal genes from the high-growing prototype parent as
result of reassortment of segmented RNA strands dur-
ng mixed infection. This procedure has been commonly
mployed since 1968 when it was found to be useful in
reparing vaccines to meet the epidemic threat of the
ong Kong (H3N2) influenza A virus (Kilbourne, 1969,
994). It has become a routine practice helpful for im-
1 To whom correspondence and reprint requests should be ad-
ressed at Center for Infectious Disease and Vaccine Research, Uni-
ersity of Massachusetts Medical School, 55 Lake Avenue North,
orcester, MA 01655. Fax: (508) 856-4890. E-mail: Francis.Ennis@Nmassmed.edu.
135roving virus yields, which are a major problem in the
roduction of inactivated influenza vaccines.
As part of our studies of the human cytotoxic T cell
CTL) responses to influenza A viruses, we established
everal human CD81 and CD41 influenza A-specific CTL
ines. We used these CTL lines to find human T cell
pitopes including an epitope in the NS1 protein on
mino acids (aa) 122–130, recently reported by others
Man et al., 1995). We used this clone as a positive
ontrol in the course of performing CTL assays with
BMC of vaccine recipients in a clinical study comparing
tandard and experimental influenza vaccines designed
o be more immunogenic. We wanted to use the same
nfluenza A virus strains in the CTL assays as those that
ere included in the vaccines in the clinical study to
easure the CTL responses to the virus antigens in the
accine. In the course of preliminary studies using the
D81 CTL clone that recognizes aa 122–130 on the
nfluenza virus NS1 protein, which is cross-reactive to H1,
2, H3 prototype viruses, we were surprised to observe
hat there was decreased lysis of target cells infected
ith the A/Texas/36/91 (H1N1) vaccine virus strain com-
ared to the lysis of target cells infected with the proto-
ype A/PR/8/34 (H1N1) or with the A/Johannesburg/33/94
H3N2) vaccine virus strains. In repeated experiments
ysis of the A/Texas vaccine virus-infected targets was
bsent or detected at a much lower level than that of
hese other target cells. We decided to determine
hether a mutation had occurred in this epitope on the
S1 protein of this virus, because we expected the
0042-6822/99 $30.00
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136 TERAJIMA ET AL.equence to be recognized regardless of whether the
S1 gene in the vaccine virus was derived from either
he high-growing parent (A/PR/8/34 (H1N1)) that this CTL
lone recognizes or the recently isolated virus that was
sed to develop a reassortant high-yielding virus that
as used to prepare the vaccine for clinical study.
RESULTS
ytotoxic T cell assays using an HLA-A2.1-restricted
D81 T cell clone 10-2C2 and influenza A viruses
The CD81 T cell clone 10-2C2 is HLA-A2.1-restricted,
ecognizes a nonamer peptide on the influenza virus
/PR/8/34 (H1N1) NS1 protein, 122AIMDKNIIL130, and is
ross-reactive for prototype strains of the human H1 and
3 subtypes (Jameson et al., 1998; Man et al., 1995).
hen we examined the cross-reactivity of clone 10-2C2
gainst recent strains of influenza virus, we found that
0-2C2 could recognize A/Johannesburg/33/94 (H3N2),
ut not the A/Texas/36/91 (H1N1) vaccine virus strain,
lthough A/Texas belonged to the same subtype as
/PR/8/34 (data not shown). Surprisingly, clone 10-2C2
ould recognize the A/Texas/36/91 (H1N1) wild-type
train (Fig. 1A).
The A/Texas vaccine strain was derived from X-113, a
igh-growing reassortant vaccine seed virus derived
FIG. 1. Percentage specific lysis of target cells, the autologous
LCLs, infected with influenza A viruses by CD81 T cells clone 10-2C2.
he X-113 virus is a reassortant of the A/Texas wild-type strain and the
-31. The A/Texas vaccine strain was derived from the X-113.rom the A/Texas wild-type virus strain (H1N1) and the q-31 (H3N2) virus. X-113 contained genes encoding the
urface glycoproteins, H1N1, of the A/Texas parent (E. D.
ilbourne, personal communication) and internal genes
f X-31 known to be derived from A/PR/8/34 (H1N1).
hen we infected target cells with the X-113 or X-31 virus
trains, the targets were killed by 10-2C2 (Fig. 1B). To
now whether the T cell epitope had changed in the
roduction of the A/Texas vaccine virus strain, viral RNA
as isolated from allantoic fluid.
ucleotide and amino acid sequence of A/Texas
ild-type and vaccine strains
cDNA fragments of the NS1 gene were amplified by
T-PCR and cloned into the pCR2.1 vector. To rule out the
ossibility that the mutation was introduced simply by
ucleotide misincorporation during PCR, two different
et of primers were used and more than two plasmid
lones were sequenced (Fig. 2). We performed two dif-
erent PCRs with the A/Texas vaccine strain. Every PCR
roduced a clear single band of the expected size on 2%
garose gel.
The nucleotide sequences between nucleotides 308
nd 474, which code for amino acids 95 to 149, were
etermined. The nucleotide sequences of the A/Texas
ild-type strain fell into two groups, a GTG group and an
TG group (Table 1 and Fig. 2). There were two nucleo-
ide changes between the two groups and both changes
esulted in amino acid changes, which were not in the T
ell epitope. The deduced amino acid sequences of both
roups in the HLA-A2.1-restricted T cell epitope were the
ame as that of A/PR/8/34 (J02150), AIMDKNIIL. How-
ver, the overall homology of both of these groups to
/PR/8/34 was 91% in the nucleotide sequence and 89%
n the amino acid sequence. BLAST search data showed
hat the A/Texas wild-type strain had the highest homol-
gy to the sequence of a more recent H1N1 virus,
/Chile/1/83(H1N1) (X15282), in the nucleotide sequence
the GTG group had 97% and the ATG group had 98%).
The nucleotide sequences of the A/Texas vaccine
train also fell into two groups, an AAC group and an
AA group (Table 1 and Fig. 2). Ten of 19 clones from two
eparate PCR experiments using two different primer
ets belonged to the AAA group. Two nucleotide differ-
nces were found between the two groups, one of which
esulted in an amino acid change within the T cell
pitope. In the AAC group the T cell epitope was AIMD-
NIIL, which is the same as that of A/PR/8/34, while in
he AAA group the T cell epitope was AIMDKKIIL. The
ther nucleotide difference also resulted in an amino
cid change, but it was at aa 101, which is not in the T cell
pitope. Both groups were more similar to A/PR/8/34 (the
AC group had 98% and the AAA group had 97% homol-
gy in nucleotide sequences) than to the A/Texas wild-
ype strain (less than 93% homology in nucleotide se-
uences), probably as a result of the recombination with
X
b
C
r
v
p
p
t
s
w
o
s
c
1
I
t
s
a
137INFLUENZA VACCINE VIRUS MUTATION AT HLA-A 2.1-RESTRICTED CTL EPITOPE-31, which contained internal genes of A/PR/8/34 (Kil-
ourne, 1969).
ytotoxic T cell assays using synthetic peptide
To confirm that the N3 K amino acid change was the
eason the clone did not recognize the A/Texas vaccine
irus strain, we performed CTL assays using a synthetic
eptide based on the sequence of the A/Texas egg-
assaged vaccine virus strain. It had been reported that
he nonamer peptide on the A/Alaska/6/77 (H3N2) virus
FIG. 2. (Top) The localization of HLA-A2.1-restricted T cell epitope an
equences and deduced amino acid sequences around the T cell epito
cids that are the same as the A/PR/8/34 are represented as dots.train, AIMEKNIML, was not recognized by CTLs that qere able to recognize the nonamer peptide, AIMDKNIIL,
n the A/PR/8/34 (Man et al., 1995), so we also tested the
ynthetic peptides that had the D 3 E amino acid
hange and the I3 M amino acid change. As expected,
0-2C2 could not recognize AIMDKKIIL, while AIMEKN-
ML and AIMDKNIML were recognized (see Fig. 3).
DISCUSSION
We found that the A/Texas vaccine virus strain con-
ained a quasispecies. Nucleotide and amino acid se-
CR primers in the NS-1 gene cDNA. (Bottom) Determined nucleotide
Bank Accession Nos. AF137362 to AF137365). Nucleotides and aminod the P
pe (Genuences of the NS1 gene were divided into two groups
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138 TERAJIMA ET AL.nd one had changes in its amino acid sequence in the
LA-A2.1-restricted T cell epitope. The sixth position of
he nonamer was changed from asparagine (N), a neutral
nd polar amino acid, to lysine (K), a basic amino acid.
his N 3 K amino acid change resulted in loss of
ecognition by the CD81 T cell clone 10-2C2. When
sparagine at the sixth position was replaced by aspartic
cid (D), an acidic amino acid, this nonamer was not
ecognized by 10-2C2 either (Jameson et al., unpublished
ata). Changes from neutral to charged amino acids at
he sixth position may alter the interaction between the
onamer peptide and the HLA-A2.1 molecule or the in-
eraction between the HLA-A2.1 molecule–nonamer pep-
ide complex and the T cell receptor. RT-PCR results
howed that approximately 50% of viral RNA of the NS1
ene had a nucleotide substitution, which resulted in the
3 K amino acid change. If the RT-PCR reflected actual
ercentages, 50% of virus particles had the T cell
pitope, and target cells were not lysed as well. In some
ssays with high killing of peptide pulsed or virus-in-
ected target cells there was a lower level killing of the
/Texas vaccine virus infected target cells. The changed
cell epitope may work as an antagonist (Klenerman et
l., 1994; Bertoletti et al., 1994).
T
Summary of RT
Amino acid sequence
in T cell epitope Tot
accine, AAA group AIMDKKIIL 10
accine, AAC group AIMDKNIIL 9
ild-type, GTG group AIMDKNIIL 2
ild-type, ATG group AIMDKNIIL 5
FIG. 3. Percentage specific lysis of target cells, the autologous
LCLs, pulsed with synthetic NS1 peptides (the concentrations of each
ligopeptides were 25 mg/ml) by CD81 T cell clone 10-2C2. The pep-
ides used are as follows: 122b, AIMDKNIML; 122c, AIMEKNIIL; 122d,
IMDKKIIL [A/Texas vaccine]; Underlined amino acids are differentgrom A/PR/8/34.Homology search results showed that the NS1 gene of
he A/Texas vaccine strain was more similar to the NS1
ene of the A/PR/8/34 than to the recently isolated
/Texas wild-type strain, suggesting that the NS1 gene of
he A/Texas vaccine strain was derived from the X-31
arent, not from the wild-type strain. During serial egg
assage of the vaccine strain using the X-113 virus, an
3 K amino acid change occurred.
Most of the T cell epitopes identified in influenza A
irus are on internal proteins (McMichael, 1994; Parker
nd Gould, 1996; Jameson et al., 1998), which are more
onserved among strains than are the surface proteins.
ecause of this conservation of internal proteins, it
eems reasonable to use a high-yielding reassortant
irus selected based on its surface proteins, hemagglu-
inin and neuraminidase, as a vaccine strain (Kilbourne,
969, 1994). However, in this case a region of the NS1
ene that encodes a T cell epitope underwent a mutation
hat caused an amino acid substitution, and a HLA-A2.1-
estricted CD81 T cell clone was not able to recognize
arget cells infected with the vaccine virus.
It is interesting to note that we recently tested this
ame CD81 T cell clone against a human influenza A
solate, Hong Kong/156/97 (H5N1). This clone failed to
ecognize autologous cells infected with the Hong Kong
irus (Jameson et al., unpublished data). This virus, iso-
ated from a human with influenza illness, was derived
rom birds and has an amino acid substitution at the
ame position in the NS1 HLA-A-2.1-restricted CTL
pitope, N 3 D at amino acid 127 (AF036360). In addi-
ion, a recent report documented the same N3 K amino
cid substitution that we found in the vaccine virus (A/
K/Pennsylvania/1370/83 (U96739) and A/CK/Pennsylva-
ia/21525/83 (U96741), Suarez and Perdue, 1998).
There is no obvious impact of this mutation on the
ffectiveness of current influenza vaccines. These vac-
ines contain mixtures of detergent-disrupted, formalin-
illed virus that are standardized for hemagglutinin con-
ent and are designed to induce and boost protective
ntibodies to the surface H1N1 glycoproteins. The NS1
rotein is not present in the virus particle, and the NS1
nd Sequencing
Primer set used
FLUNS115 and 475 FLUNS292 and 658
Expt. 1 Expt. 2 Expt. 1 Expt. 2
3 2 3 2
0 3 3 3
1 1
1 4ABLE 1
-PCR a
alene in the killed virus cannot produce the NS1 protein.
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139INFLUENZA VACCINE VIRUS MUTATION AT HLA-A 2.1-RESTRICTED CTL EPITOPEt is useful, however, to learn more about mutations in
accine viruses because future vaccines, such as live
ttenuated or inactivated vaccines designed to stimulate
D81 CTL responses, may utilize such cross-reactive
D81 CTL epitopes for improved vaccine efficiency. Mu-
ations may occur at CD81 CTL epitopes on other influ-
nza A proteins. These mutations may offer advantages
o the virus for growth in other species or in cell cultures
ut they would reduce the ability of humans to generate
D81 CTL responses to the vaccine.
MATERIALS AND METHODS
irus strains and growth
Influenza virus A/PR/8/34 (H1N1), X-31, and A/Johan-
esburg/33/94 (H3N2) and three strains of A/Texas/36/91
H1N1) were used in this study. X-31 is a high-yielding
eassortant of A/Aichi/2/68 (H3N2) and A/PR/8/34
H1N1), which has the HA and NA of the H3N2 virus and
he internal genes of the A/PR/8 (Kilbourne, 1969). The
trains of A/Texas are (1) A/Texas/36/91 (H1N1), wild-
ype strain; (2) X-113, a high-yielding reassortant of
/Texas and X-31, which has the H1N1 subtype; and (3)
/Texas reassortant vaccine seed virus strain, which
as derived from X-113. X-31 and X-113 were kindly
upplied by E. D. Kilbourne. The A/PR/8 virus was pro-
ided by the Bureau of Biologics FDA, the A/Texas/36/91
H1N1) virus was kindly supplied by N. Cox of the WHO
nfluenza Research Center, and the A/Texas vaccine
gg-passaged strain was kindly supplied by David Burt
f Pasteur Merieux Connaught, Toronto, Canada. Influ-
nza A viruses were propagated in 10-day-old, embryo-
ated chicken eggs. Infected allantoic fluids were har-
ested 2 days after infection, aliquoted, and stored at
80°C until use.
reparation of target cells
The autologous B lymphoblastoid cell line (BLCL) used
n this study was established by culturing peripheral
lood mononuclear cells with Epstein–Barr virus in 24-
ell plates as previously described (Green et al., 1993).
he HLA alleles of the donor are A2.1, A11, B18, B27, Cw1,
w7, DR1, DQw1, DQw3, DRw52, and DRw53 (Jameson et
l., 1998). BLCL were infected with influenza viruses at
n m.o.i. of 15:1 in 1 ml of medium for 12 to 16 h. The
nfected target cells were labeled with 0.25 mCi of 51Cr
or 60 min at 37°C. After four washes, the target cells
ere counted and diluted to 2 3 104/ml for use in the
ytotoxicity assay.
ytotoxic T cell assays
CTL assays were performed with 96-well round-bot-
om plates as previously reported (Bukowski et al., 1989).
riefly, effector cells in 100 ml of RPMI 1640 medium
3 51ontaining 10% FBS were added to 2 3 10 Cr-labeled aarget cells in 100 ml at an effector-to-target (E:T) ratio of
0:1. In cytotoxicity assays using synthetic peptides, pep-
ides were added to target cells at the indicated concen-
rations and incubated at 37°C for 30 min, after which the
ffector cells were added. Plates were centrifuged at
00g for 5 min and incubated for 4 to 5 h at 37°C.
upernatant fluids were harvested using a supernatant
ollection system (Skatron Instruments, Sterling, VA), and
51Cr content was measured in a gamma counter. Per-
entage specific 51Cr release was calculated with the
ollowing formula: (cpm experimental release—cpm
pontaneous release)/(cpm maximum release—cpm
pontaneous release) 3 100. All assays were performed
n triplicate, and the results were calculated from the
verage of the triplicate wells.
NA isolation
RNA was extracted from 600 ml of allantoic fluid by the
ltraspec RNA isolation system (Biotecx Laboratories,
nc., Houston, TX) following the manufacturer’s recom-
endations. Extracted RNA was dissolved in 100 ml of
EPC-treated water.
everse transcription and PCR
Ten microliters of the extracted RNA was added to 90 ml
f reverse transcription solution. The final concentrations of
ach component were as follows: 50 mM Tris–HCl (pH 8.3),
5 mM KCl, 3 mM MgCl2, 10 mM DTT, 0.5 mM of each
NTP, 1 u/ml RNAsin ribonuclease inhibitor (Promega, Mad-
son, WI), 0.001 A260u/ml pd(N)6 Random Hexamer (Pharma-
ia Biotech, Uppsala, Sweden), and 0.3 u/ml AMV reverse
ranscriptase (Promega). Reverse transcription was per-
ormed at 37°C for 60 min, followed by inactivation at 95°C
or 10 min (Terajima et al., 1997). For PCR 1 ml of reverse
ranscription mixture was added to 49 ml of PCR solution
onsisting of 10 mM Tris–HCl (pH 9.0), 50 mM KCl, 1.5 mM
gCl2, 0.1% Triton X-100, 0.2 mM of each dNTP, 0.5 pmol/ml
f each primer, and 1.25 units of Tth DNA Polymerase
Promega). The reaction was carried out at 94°C for 3 min,
ollowed by 30 cycles of 94°C for 30 s, 48°C for 1 min, and
2°C for 3 min and finally for 1 cycle of 72°C for 8 min 30 s
n a DNA Thermal Cycler 480 (Perkin–Elmer, Foster City,
A). The primer pairs used were as follows: FLUNS115
59-CCCCATTCCTTGATCGG) and FLUNS475 (59-TGCTC-
CTCTTCGGTGA); FLUNS292 (59-ACCTAACTGACATGAC)
nd FLUNS658 (59-GAGTGAGTGGAGGTC). These primers
ere designed based on the published nucleotide se-
uence of NS1 cDNA of the influenza A/Puerto Rico/8/34
Cambridge) (H1N1) (GenBank Accession No. J02150) by
enetic information processing software, GENETYX-WIN
Software Development, Tokyo, Japan). These four regions
re conserved in most influenza viruses of the human
ubtypes H1N1, H2N2, and H3N2. Ten microliters of PCR
roduct was subjected to 2% agarose gel electrophoresis
nd the gel was stained with ethidium bromide.
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140 TERAJIMA ET AL.loning and sequencing of PCR product
The PCR product was ligated into pCR2.1 vector and
he ligated product was used to transform Escherichia
oli INVaF9 by using an Original TA Cloning Kit (Invitro-
en, Carlsbad, CA) following the manufacturer’s recom-
endations. Plasmids were prepared by using the QIA-
rep Spin Miniprep Kit (Qiagen, Valencia, CA), following
he manufacturer’s recommendations. Plasmid clones
ere selected by EcoRI (Promega) restriction enzyme
igestion and agarose gel electrophoresis (the PCR
roduct was inserted between two EcoRI sites in the
CR2.1 vector). The clones whose insert fragments had
n appropriate size were sequenced by using a dsDNA
ycle Sequencing System (Life Technologies, Grand Is-
and, N. Y.). The sequencing primers used were T7 Pro-
oter and M13 Reverse primers (Invitrogen).
ynthetic oligonucleotides and peptides
Synthetic oligonucleotides were purchased from
peron Technologies, Inc. (Alameda, CA). Peptides were
ynthesized at the Protein Chemistry Core Facility at the
niversity of Massachusetts using an automated Rainin
ymphony peptide synthesizer. Peptides were purified by
PLC.
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